PDF
Cyxone AB (publ) receives approximately SEK 18.2 million through exercised warrants of series TO4
Today, Cyxone AB (publ) ("Cyxone" or the "Company") announces the outcome of the exercise of warrants of series TO4, which were issued in connection with the Company's directed issue of units during the fourth quarter of 2020. A total of 5,613,656 warrants of series TO4 were exercised, corresponding to approximately 93.5 percent of the warrants of series TO4, for subscription of 5,613,656 shares at a subscription price of SEK 3.24 per share. Through the exercise of warrants of series TO4, Cyxone receives approximately SEK 18.2 million before issuing costs.
Background
During the fourth quarter of 2020, Cyxone completed a directed issue of so-called units. One (1) unit consisted of one (1) share and one (1) warrant of series TO4. In connection with the directed issue, the Company's existing shareholders were also compensated with warrants of series TO4. The exercise period for the exercise of warrants of series TO4 lasted during the period from and including May 17, 2021 up to and including May 28, 2021. The subscription price per share when exercising the warrants of series TO4 amounted to SEK 3.24.
In total, 5,613,656 warrants of series TO4 were exercised for subscription of 5,613,656 shares, meaning that approximately 93.5 percent of the outstanding warrants of series TO4 were exercised for subscription of shares.
Exercised warrants have been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. The conversion of interim shares into shares is expected to take place within approximately two (2) weeks.
Number of shares, share capital and dilution
Through the exercise of warrants of series TO4, the number of shares in Cyxone increases by 5,613,656 shares, from 58,063,400 shares to 63,677,056 shares. The share capital increases with SEK 423,672.39, from SEK 4,382,145.83 to SEK 4,805,818.22.
For existing shareholders who have not exercised any warrants of series TO4, the dilution effect amounts to approximately 8.8 percent based on the number of shares after the exercise of the warrants of series TO4.
Advisers
Mangold Fondkommission AB is the financial adviser and Fredersen Advokatbyrå AB is the legal adviser for Cyxone regarding the warrants.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5050 1595
Email: emissioner@mangold.se
Contact
Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden
This information is information that Cyxone AB (publ) is required to make public pursuant to the EU's Market Abuse Regulation. The information was submitted for publication by the contact person above on June 1, 2021, at 16.50 CEST.
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se.For more information, please visit www.cyxone.com.